Class II human leucocyte antigen haplotypes and clinical classification in 30 patients with anti-CASPR2 antibodies
| Sex, age (years) | Group | Haplotype/1 | Haplotype/2 | ||||
| DRB1 | DQB1 | DQA1 | DRB1 | DQB1 | DQA1 | ||
| M, 62 | LE/− | 11:01:01 | 03:01:01 | 05:XX | 11:01:01 | 03:01:01 | 05:XX |
| M, 66 | LE/− | 11:01:01 | 03:01:01 | 05:XX | 11:01:01 | 03:01:01 | 05:XX |
| M, 69 | LE/− | 11:01:01 | 03:01:01 | 05:XX | 11:04:01 | 03:01:01 | 05:XX |
| M, 53 | LE/− | 11:01:02 | 03:01:01 | XX | 03:01:01 | 02:01:01 | XX |
| M, 66 | LE/− | 11:01:01 | 03:01:01 | 05:XX | 11:01:01 | 03:01:01 | 05:XX |
| M, 61 | LE/− | 11:01:01 | 03:01:01 | 05:05:01 | 13:01:01 | 06:03:01 | 01:XX |
| M, 71 | LE/− | 11:01:01 | 03:01:01 | 05:XX | 11:01:01 | 03:01:01 | 05:XX |
| M, 72 | LE/− | 15:01:01 | 06:02:01 | 01:02:01 | 04:01:01 | 03:02:01 | 03:01:01 |
| M, 66 | LE/− | 11:01:01 | 03:01:01 | 05:XX | 13:01:01 | 06:03:01 | 01:03:01 |
| M, 61 | LE/− | 11:01:01 | 03:01:01 | 05:XX | 04:05:01 | 03:02:01 | 03:XX |
| M, 71 | LE/+ | 11:01:01 | 03:01:01 | 05:XX | 08:02:01 | 04:02:01 | 04:01:01 |
| M, 60 | LE/+ | 11:01:01 | 03:01:01 | 05:XX | 13:01:01 | 06:03:01 | 01:03:01 |
| M, 72 | LE/+ | 11:01:01 | 03:01:01 | XX | 11:02:01 | 03:19:01 | XX |
| M, 69 | LE/+ | 11:01:02 | 05:02:01 | 01:02:01 | 04:05:01 | 02:XX | 03:XX |
| M, 68 | LE/+ | 11:01:01 | 03:01:01 | 05:XX | 07:01:01 | 02:XX | 02:01:01 |
| M, 62 | LE/+ | 11:01:01 | 03:01:01 | 05:XX | 07:01:01 | 02:XX | 02:01:01 |
| M, 57 | LE/+ | 11:01:01 | 03:01:01 | 05:XX | 11:01:01 | 03:01:01 | 05:XX |
| F, 58 | PNH/+ | 16:01:01 | 05:02:01 | 01:02 | 03:01:01 | 02:01:01 | 05:01:01 |
| M, 48 | PNH/+ | 04:01:01 | 03:01:01 | 03:XX | 04:04:01 | 03:02:01 | 03:XX |
| M, 60 | PNH/+ | 11:01:01 | 03:01:01 | 05:XX | 11:04:01 | 03:01:01 | 05:XX |
| M, 65 | PNH/+ | 01:03:01 | 03:01:01 | 05:XX | 04:08:01 | 03:01:01 | 03:01:01 |
| M, 41 | PNH/+ | 16:01:01 | 05:02:01 | 01:02 | 11:04:01 | 03:01:01 | 05:XX |
| M, 43 | PNH/+ | 15:01:01 | 06:02:01 | 01:02:01 | 03:01:01 | 02:01:01 | 05:01:01 |
| M, 73 | PNH/+ | 11:01:01 | 03:01:01 | 05:XX | 07:01:01 | 02:XX | 02:01:01 |
| M, 29 | PNH/+ | 03:01:01 | 02:XX | 05:01:01 | 07:01:01 | 02:01:01 | 02:01:01 |
| F, 37 | PNH/− | 04:05:01 | 03:02:01 | 03:XX | 13:01:01 | 06:03:01 | 01:03:01 |
| M, 28 | PNH/− | 04:01:01 | 03:02:01 | 03:XX | 01:01:01 | 05:01:01 | 01:01:01 |
| M, 39 | PNH/− | 11:01:01 | 03:01:01 | 05:XX | 07:01:01 | 02:XX | 02:01:01 |
| M, 58 | *PNH/− | 01:01:01 | 05:01:01 | 01:01:01 | 01:03:01 | 05:01:01 | 01:01:01 |
| M, 68 | *PNH/− | 11:01:01 | 03:01:01 | 05:XX | 07:01:01 | 02:XX | 02:01:01 |
Alleles are reported at six-digit level, unless it was not technically possible (XX). DRB1*11:01 is highlighted in bold. *PNH/− indicates patients presenting also with limbic features.
CASPR2-Abs, anti-CASPR2 antibodies; F, Female; HLA, human leukocyteantigen; LE, limbic encephalitis; M, male; PNH, peripheral nerve hyperexcitability.